Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × Cholecalciferol × Clear all

Phase

Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteoporosis 4 Prostatic Neoplasms 3 Breast Neoplasms 3 Vitamin D Deficiency 2 Polycystic Ovary Syndrome 2 Neoplasms 2 Cardiovascular Diseases 2 Vitamin D3 1 Neuroma 1 Melanoma, Cutaneous Malignant 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Insulin Resistance 1 Fractures, Bone 1 Colorectal Adenocarcinoma 1

Interventions

Dacarbazine 24 Nivolumab 20 pembrolizumab 17 Ipilimumab 15 Interferon-alpha 10 trametinib 8 dabrafenib 7 aldesleukin 7 Vemurafenib 7 Temozolomide 7 Introns 6 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 binimetinib 4 Radiotherapy 4 Chemotherapy, Adjuvant 4 encorafenib 3 cobimetinib 3 cemiplimab 3 Vinblastine 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Paclitaxel 3 Opdualag 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 CTLA-4 Antigen 3 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01264874 2018-01-31

MelaViD

European Institute of Oncology

Phase 3 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡